Sanofi (SAN) Stock Forecast & Price Target

Compare

172 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SAN Analyst Ratings

Moderate Buy

11 Buy

4 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SAN Stock 12 Month Forecast

Average Price Target

€115.85

▲(25.96%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is €115.85 with a high forecast of €127.00 and a low forecast of €95.00. The average price target represents a 25.96% change from the last price of €91.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"€84","95":"€95","106":"€106","117":"€117","128":"€128"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":127.0000006021578,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€127.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115.847795778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€115.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.000000450433,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,95,106,117,128],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.854,94.5575385078583,97.26107701571658,99.96461552357488,102.66815403143318,105.37169253929146,108.07523104714976,110.77876955500804,113.48230806286634,116.18584657072464,118.88938507858292,121.59292358644122,124.2964620942995,{"y":127.0000006021578,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.854,93.69967659830769,95.54535319661538,97.39102979492307,99.23670639323078,101.08238299153847,102.92805958984616,104.77373618815385,106.61941278646154,108.46508938476924,110.31076598307692,112.15644258138462,114.00211917969231,{"y":115.847795778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.854,92.0960000346487,92.33800006929738,92.58000010394608,92.82200013859477,93.06400017324346,93.30600020789215,93.54800024254085,93.79000027718955,94.03200031183823,94.27400034648693,94.51600038113563,94.75800041578431,{"y":95.000000450433,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85.599,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.973,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.975,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.02,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.436,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.535,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.536,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.946,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.785,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.995,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.957,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.716,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.854,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€127.00

Average Price Target€115.85

Lowest Price Target€95.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

€104

Buy

13.08%

Upside

Reiterated

05/24/25

Sanofi's strong financial performance and positive earnings call insights are the primary drivers of its robust stock score. While the technical analysis shows mild positive momentum, valuation metrics are reasonable and support the stock's potential. Challenges in specific markets and exchange rates are noted but do not significantly detract from the overall positive outlook.

Richard VosserJ.P. Morgan

J.P. Morgan

€110

Hold

19.60%

Upside

Reiterated

05/30/25

J.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)

Sachin JainBank of America Securities

Bank of America Securities

€123

Buy

33.74%

Upside

Reiterated

05/30/25

Sanofi's Promising Pipeline and Competitive Positioning Justify Buy Rating Despite Mixed Study Results

Jo WaltonUBS

UBS

€115

Buy

25.04%

Upside

Reiterated

05/30/25

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

€100

Hold

8.73%

Upside

Reiterated

05/28/25

Sanofi (SNYNF) Gets a Hold from Deutsche Bank

Benjamin Jackson CFAJefferies

Jefferies

€120

Buy

30.48%

Upside

Reiterated

05/28/25

Jefferies Keeps Their Buy Rating on Sanofi (SNYNF)

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/22/25

We continue to expect biopharma industry SMID-Cap M&A accelerate, based upon recent large-cap quarterly results call commentary. See report here. Maintain OP on SAN FP.

Florent CespedesBernstein

Bernstein

€124

Buy

34.83%

Upside

Reiterated

05/22/25

Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Medtronic (NYSE: MDT) and Sanofi (Other OTC: SNYNF)

Nicolas PauillacKepler Capital

Kepler Capital

€95

Hold

3.29%

Upside

Reiterated

05/20/25

Sanofi (SNYNF) Receives a Hold from Kepler Capital

Kerry HolfordBerenberg Bank

Berenberg Bank

€120

Buy

30.48%

Upside

Reiterated

05/16/25

Berenberg Bank Keeps Their Buy Rating on Sanofi (SNYNF)

Rajesh KumarHSBC

HSBC

€130→€115

Buy

25.04%

Upside

Reiterated

04/28/25

Sanofi price target lowered to EUR 115 from EUR 130 at HSBCSanofi price target lowered to EUR 115 from EUR 130 at HSBC

Elmar KrausDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

04/25/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF), Roche Holding AG (Other OTC: RHHVF) and BioNTech SE (NASDAQ: BNTX)

James QuigleyGoldman Sachs

Goldman Sachs

€122→€117

Hold

27.22%

Upside

Reiterated

04/25/25

Goldman Sachs Reaffirms Their Hold Rating on Sanofi (SNYNF)

Eric Le BerrigaudStifel Nicolaus

Stifel Nicolaus

€123→€127

Buy

38.09%

Upside

Reiterated

04/24/25

Sanofi's Strong Financial Performance and Promising R&D Pipeline Justify Buy Rating

Emily FieldBarclays

Barclays

€125

Buy

35.91%

Upside

Reiterated

04/24/25

Barclays Keeps Their Buy Rating on Sanofi (SNYNF)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

€104

Buy

13.08%

Upside

Reiterated

05/24/25

Richard VosserJ.P. Morgan

J.P. Morgan

€110

Hold

19.60%

Upside

Reiterated

05/30/25

J.P. Morgan Keeps Their Hold Rating on Sanofi (SNYNF)

Sachin JainBank of America Securities

Bank of America Securities

€123

Buy

33.74%

Upside

Reiterated

05/30/25

Sanofi's Promising Pipeline and Competitive Positioning Justify Buy Rating Despite Mixed Study Results

Jo WaltonUBS

UBS

€115

Buy

25.04%

Upside

Reiterated

05/30/25

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

€100

Hold

8.73%

Upside

Reiterated

05/28/25

Sanofi (SNYNF) Gets a Hold from Deutsche Bank

Benjamin Jackson CFAJefferies

Jefferies

€120

Buy

30.48%

Upside

Reiterated

05/28/25

Jefferies Keeps Their Buy Rating on Sanofi (SNYNF)

David RisingerLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/22/25

We continue to expect biopharma industry SMID-Cap M&A accelerate, based upon recent large-cap quarterly results call commentary. See report here. Maintain OP on SAN FP.

Florent CespedesBernstein

Bernstein

€124

Buy

34.83%

Upside

Reiterated

05/22/25

Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Medtronic (NYSE: MDT) and Sanofi (Other OTC: SNYNF)

Nicolas PauillacKepler Capital

Kepler Capital

€95

Hold

3.29%

Upside

Reiterated

05/20/25

Sanofi (SNYNF) Receives a Hold from Kepler Capital

Kerry HolfordBerenberg Bank

Berenberg Bank

€120

Buy

30.48%

Upside

Reiterated

05/16/25

Berenberg Bank Keeps Their Buy Rating on Sanofi (SNYNF)

Rajesh KumarHSBC

HSBC

€130→€115

Buy

25.04%

Upside

Reiterated

04/28/25

Sanofi price target lowered to EUR 115 from EUR 130 at HSBCSanofi price target lowered to EUR 115 from EUR 130 at HSBC

Elmar KrausDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

04/25/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF), Roche Holding AG (Other OTC: RHHVF) and BioNTech SE (NASDAQ: BNTX)

James QuigleyGoldman Sachs

Goldman Sachs

€122→€117

Hold

27.22%

Upside

Reiterated

04/25/25

Goldman Sachs Reaffirms Their Hold Rating on Sanofi (SNYNF)

Eric Le BerrigaudStifel Nicolaus

Stifel Nicolaus

€123→€127

Buy

38.09%

Upside

Reiterated

04/24/25

Sanofi's Strong Financial Performance and Promising R&D Pipeline Justify Buy Rating

Emily FieldBarclays

Barclays

€125

Buy

35.91%

Upside

Reiterated

04/24/25

Barclays Keeps Their Buy Rating on Sanofi (SNYNF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+1.62%

reiterated a xxx

rating 17 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +1.62% per trade.

3 Months

xxx

Success Rate

8/10 ratings generated profit

Average Return

+1.41%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +1.41% per trade.

1 Year

Jo WaltonUBS

Success Rate

13/15 ratings generated profit

Average Return

+9.60%

reiterated a buy rating 17 hours ago

Copying Jo Walton's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +9.60% per trade.

2 Years

xxx

Success Rate

12/13 ratings generated profit

Average Return

+11.14%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +11.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAN Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SAN has received 25 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. SAN average Analyst price target in the past 3 months is 115.85.

Each month's total comprises the sum of three months' worth of ratings.

SAN Financial Forecast

SAN Earnings Forecast

Next quarter’s earnings estimate for SAN is €1.66 with a range of €1.55 to €1.80. The previous quarter’s EPS was €1.38. SAN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.23% of the time in the same period. In the last calendar year SAN has Outperformed its overall industry.

SAN Sales Forecast

Next quarter’s sales forecast for SAN is €10.33B with a range of €9.93B to €10.60B. The previous quarter’s sales results were ―. SAN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year SAN has Outperformed its overall industry.

SAN Stock Forecast FAQ

What is FR:SAN’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi’s 12-month average price target is 115.85.

What is FR:SAN’s upside potential, based on the analysts’ average price target?

Sanofi has 25.96% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sanofi a Buy, Sell or Hold?

Sanofi has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.

What is Sanofi’s share price target?

The average share price target for Sanofi is 115.85. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €127.00 ,and the lowest forecast is €95.00. The average share price target represents 25.96% Increase from the current price of €91.97.

What do analysts say about Sanofi?

Sanofi’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Sanofi?

To buy shares of FR:SAN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sanofi (SAN) Stock Forecast & Price Target

SAN Analyst Ratings

SAN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

SAN Analyst Recommendation Trends

SAN Financial Forecast

SAN Earnings Forecast

SAN Sales Forecast

SAN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts